Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Kassapian M"'
With the advent of innovative therapeutics for and the rising costs of cancer management, low-income and middle-income countries face increasing challenges to deliver effective and sustainable health care. Understanding of how countries are selecting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::6fbe463318aecd5d025f4c48af3cde98
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3118501
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3118501
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Objectives: Chemo-radiotherapy (CRT) and concurrent PD-1 inhibition has shown promising results in pre-clinical models. So far, the feasibility of delivering concurrent CRT and PD-1/PD-L1 inhibition has never been assessed in a clinical trial. Materi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::a3b49a135aacbe35b43c5275f2231c14
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077420
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077420
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF, EMPHASIS-lung Collaborative Group
Publikováno v:
JOURNAL OF THORACIC ONCOLOGY
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Journal of Thoracic Oncology, 12(4), 752-762. International Association for the Study of Lung Cancer
Peters, S, Stahel, R A, Dafni, U, Ponce Aix, S, Massutí, B, Gautschi, O, Coate, L, López Martín, A, van Heemst, R, Berghmans, T, Meldgaard, P, Cobo Dols, M, Garde Noguera, J, Curioni-Fontecedro, A, Rauch, D, Mark, M T, Cuffe, S, Biesma, B, van Henten, A M J, Juan Vidal, Ó, Palmero Sanchez, R, Villa Guzmán, J C, Collado Martin, R, Peralta, S, Insa, A, Summers, Y, Láng, I, Horgan, A, Ciardiello, F, de Hosson, S, Pieterman, R, Groen, H J M, van den Berg, P M, Zielinski, C C, Chittazhathu Kurian Kuruvilla, Y, Gasca-Ruchti, A, Kassapian, M, Novello, S, Torri, V, Tsourti, Z, Gregorc, V, Smit, E F & EMPHASIS-lung Collaborative Group 2017, ' Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial ', Journal of Thoracic Oncology, vol. 12, no. 4, pp. 752-762 . https://doi.org/10.1016/j.jtho.2016.12.017
Peters, S, Stahel, R A, Dafni, U, Ponce Aix, S, Massutí, B, Gautschi, O, Coate, L, López Martín, A, van Heemst, R, Berghmans, T, Meldgaard, P, Cobo Dols, M, Garde Noguera, J, Curioni-Fontecedro, A, Rauch, D, Mark, M T, Cuffe, S, Biesma, B, van Henten, A M J, Juan Vidal, Ó, Palmero Sanchez, R, Villa Guzmán, J C, Collado Martin, R, Peralta, S, Insa, A, Summers, Y, Láng, I, Horgan, A, Ciardiello, F, de Hosson, S, Pieterman, R, Groen, H J M, van den Berg, P M, Zielinski, C C, Chittazhathu Kurian Kuruvilla, Y, Gasca-Ruchti, A, Kassapian, M, Novello, S, Torri, V, Tsourti, Z, Gregorc, V, Smit, E F & EMPHASIS-lung Collaborative Group 2017, ' Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial ', Journal of Thoracic Oncology, vol. 12, no. 4, pp. 752-762 . https://doi.org/10.1016/j.jtho.2016.12.017
Journal of Thoracic Oncology, 12(4), 752-762. ELSEVIER SCIENCE INC
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Journal of Thoracic Oncology, 12(4), 752-762. International Association for the Study of Lung Cancer
Peters, S, Stahel, R A, Dafni, U, Ponce Aix, S, Massutí, B, Gautschi, O, Coate, L, López Martín, A, van Heemst, R, Berghmans, T, Meldgaard, P, Cobo Dols, M, Garde Noguera, J, Curioni-Fontecedro, A, Rauch, D, Mark, M T, Cuffe, S, Biesma, B, van Henten, A M J, Juan Vidal, Ó, Palmero Sanchez, R, Villa Guzmán, J C, Collado Martin, R, Peralta, S, Insa, A, Summers, Y, Láng, I, Horgan, A, Ciardiello, F, de Hosson, S, Pieterman, R, Groen, H J M, van den Berg, P M, Zielinski, C C, Chittazhathu Kurian Kuruvilla, Y, Gasca-Ruchti, A, Kassapian, M, Novello, S, Torri, V, Tsourti, Z, Gregorc, V, Smit, E F & EMPHASIS-lung Collaborative Group 2017, ' Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial ', Journal of Thoracic Oncology, vol. 12, no. 4, pp. 752-762 . https://doi.org/10.1016/j.jtho.2016.12.017
Peters, S, Stahel, R A, Dafni, U, Ponce Aix, S, Massutí, B, Gautschi, O, Coate, L, López Martín, A, van Heemst, R, Berghmans, T, Meldgaard, P, Cobo Dols, M, Garde Noguera, J, Curioni-Fontecedro, A, Rauch, D, Mark, M T, Cuffe, S, Biesma, B, van Henten, A M J, Juan Vidal, Ó, Palmero Sanchez, R, Villa Guzmán, J C, Collado Martin, R, Peralta, S, Insa, A, Summers, Y, Láng, I, Horgan, A, Ciardiello, F, de Hosson, S, Pieterman, R, Groen, H J M, van den Berg, P M, Zielinski, C C, Chittazhathu Kurian Kuruvilla, Y, Gasca-Ruchti, A, Kassapian, M, Novello, S, Torri, V, Tsourti, Z, Gregorc, V, Smit, E F & EMPHASIS-lung Collaborative Group 2017, ' Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial ', Journal of Thoracic Oncology, vol. 12, no. 4, pp. 752-762 . https://doi.org/10.1016/j.jtho.2016.12.017
Journal of Thoracic Oncology, 12(4), 752-762. ELSEVIER SCIENCE INC
Introduction: Docetaxel and erlotinib are registered second line treatments for wild-type EGFR NSCLC. Previous studies suggested a predictive value of the VeriStrat test in second line therapy of NSCLC, classifying patients as either VeriStrat good o
Autor:
Rosell, R, Dafni, U, Felip, E, Curioni-Fontecedro, A, Gautschi, O, Peters, S, Massuti, B, Palmero, R, Aix, SP, Carcereny, E, Fruh, M, Pless, M, Popat, S, Kotsakis, A, Cuffe, S, Bidoli, P, Favaretto, A, Froesch, P, Reguart, N, Puente, J, Coate, L, Barlesi, F, Rauch, D, Thomas, M, Camps, C, Gomez-Codina, J, Majem, M, Porta, R, Shah, R, Hanrahan, E, Kammler, R, Ruepp, B, Rabaglio, M, Kassapian, M, Karachaliou, N, Tam, R, Shames, DS, Molina-Vila, MA, Stahel, RA, BELIEF collaborative group
Publikováno v:
LANCET RESPIRATORY MEDICINE
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
BACKGROUND: The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence of the T790M resistance mutation w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1dce3a39f83b6ce9506a1fd9ad0d3fa7
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=6203
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=6203
Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence of the T790M resistance mutation wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::948deb7d9ad99b6849fc0239784c42f4
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3126192
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3126192
Introduction Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. Previous studies suggested a predictive value of the VeriStrat test in second-line therapy of NSCLC, classifying patients as either VeriStrat good or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::0ba1507d0ad73b0dfce28aff8c071fdd
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3108791
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3108791